📊 CLCS Key Takeaways
Investment Thesis
Cell Source is in severe financial distress with negative stockholders' equity of -$18.9M, indicating liabilities exceed assets by nearly $19M. The company is cash-flow negative with operating losses of $3.2M against minimal revenue of -$124.8K, suggesting either business model failure or accounting issues. With only $23K in cash against $19.2M in total liabilities and a current ratio of 0.03x, the company faces imminent solvency risk.
CLCS Strengths
- No recent insider selling (0 Form 4 filings in last 90 days suggests limited insider confidence)
CLCS Risks
- Negative stockholders' equity of -$18.9M indicates technical insolvency
- Negative revenue of -$124.8K suggests business failure or significant accounting adjustments
- Severe liquidity crisis with current ratio of 0.03x and only $23K cash against $19.2M liabilities
- Operating losses of $3.2M with no meaningful revenue generation
- High leverage with $3.5M long-term debt and -28.3x interest coverage ratio
- Negative operating cash flow of -$1.9M demonstrates inability to fund operations
Key Metrics to Watch
- Stockholders' equity trend and path to solvency
- Operating cash flow and runway to cash depletion
- Revenue stabilization and return to positive sales
CLCS Financial Metrics
💡 AI Analyst Insight
The 1,553.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
CLCS Profitability Ratios
CLCS vs Healthcare Sector
How Cell Source, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CLCS Balance Sheet & Liquidity
CLCS 5-Year Financial Trend
5-Year Trend Summary: Cell Source, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.18 indicates the company is currently unprofitable.
CLCS Growth Metrics (YoY)
CLCS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2015 | N/A | -$556.6K | N/A |
| Q3 2014 | N/A | -$323.6K | N/A |
| Q2 2014 | N/A | -$496.3K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CLCS Capital Allocation
CLCS SEC Filings
Access official SEC EDGAR filings for Cell Source, Inc. (CIK: 0001569340)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLCS
What is the AI rating for CLCS?
Cell Source, Inc. (CLCS) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLCS's key strengths?
No recent insider selling (0 Form 4 filings in last 90 days suggests limited insider confidence).
What are the risks of investing in CLCS?
Negative stockholders' equity of -$18.9M indicates technical insolvency. Negative revenue of -$124.8K suggests business failure or significant accounting adjustments.
What is CLCS's revenue and growth?
Cell Source, Inc. reported revenue of $-124.8K.
Does CLCS pay dividends?
Cell Source, Inc. does not currently pay dividends.
Where can I find CLCS SEC filings?
Official SEC filings for Cell Source, Inc. (CIK: 0001569340) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLCS's EPS?
Cell Source, Inc. has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.